Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches

Journal of Cutaneous Medicine and Surgery
Richard G LangleyCatherine Zip

Abstract

Psoriasis is a T-cell mediated skin disease that affects approximately 2% of the population worldwide. Despite the prevalence of the disease and long-standing efforts to develop strategies to treat it, there is a need for safe and effective therapies to treat psoriasis, particularly the more severe forms. Biological agents such as alefacept, efalizumab, etanercept, and infliximab have been recognized as a class of treatment distinct from other forms of therapy in the treatment algorithm of psoriasis. Recent national and international consensus meetings have developed statements that position biological agents as an important addition to the treatment armamentarium for moderate to severe psoriasis, along with phototherapy and traditional systemic agents. There has been consensus that treatment should be individualized to each patient's needs and circumstances. Biological agents offer the hope of safe, effective, long-term management of moderate to severe psoriasis. As new agents receive approval from Health Canada, the available range of therapeutic options for treating this chronic disease will broaden. A Canadian Psoriasis Expert Panel recently convened in February 2005 to analyze, based on a series of clinical case scenarios,...Continue Reading

References

Mar 2, 1995·The New England Journal of Medicine·M W Greaves, G D Weinstein
Oct 12, 1996·BMJ : British Medical Journal·P O'Neill, P Kelly
Apr 20, 2000·Journal of Clinical Pharmacy and Therapeutics·D M AshcroftC E Griffiths
Jun 26, 2001·Clinical and Experimental Dermatology·E Christophers
Jul 28, 2001·The New England Journal of Medicine·C N EllisUNKNOWN Alefacept Clinical Study Group
Nov 27, 2002·Journal of the American Academy of Dermatology·Gerald G KruegerUNKNOWN Alefacept Clinical Study Group
Jan 30, 2003·American Journal of Clinical Dermatology·Charles N EllisUNKNOWN Randomized, placebo-controlled phase II trial
May 29, 2003·Dermatology : International Journal for Clinical and Investigative Dermatology·A Y FinlayUNKNOWN Alefacept Clinical Study Group
Jun 6, 2003·Journal of the American Academy of Dermatology·Alice B GottliebDaniel G Baker
Jun 11, 2003·Journal of the European Academy of Dermatology and Venereology : JEADV·J-P Ortonne
Aug 2, 2003·Journal of the American Academy of Dermatology·Jane Choi, John Y M Koo
Oct 25, 2003·Journal of the American Academy of Dermatology·Jeffrey P CallenUNKNOWN AAD
Nov 25, 2003·The New England Journal of Medicine·Mark LebwohlUNKNOWN Efalizumab Study Group
Nov 25, 2003·The New England Journal of Medicine·Craig L LeonardiUNKNOWN Etanercept Psoriasis Study Group
Dec 16, 2003·Skinmed·Kenneth B Gordon, Thomas S McCormick
Dec 17, 2003·Archives of Dermatology·Alice B GottliebRalph Zitnik
Dec 18, 2003·JAMA : the Journal of the American Medical Association·Kenneth B GordonUNKNOWN Efalizumab Study Group
Apr 16, 2004·The Journal of Investigative Dermatology. Symposium Proceedings·Robert S SternTara Rolstad
Jun 5, 2004·Dermatology : International Journal for Clinical and Investigative Dermatology·D JullienP Natta
Jun 8, 2004·Current Drug Targets. Inflammation and Allergy·Luigi Naldi
Jul 22, 2004·The British Journal of Dermatology·W SterryJ Voorhees
Sep 25, 2004·Journal of the American Academy of Dermatology·Alice B GottliebAlan Menter
Feb 15, 2005·Annals of the Rheumatic Diseases·P Nash, D O Clegg
Mar 12, 2005·Journal of the American Academy of Dermatology·Craig L LeonardiUNKNOWN Efalizumab Study Group
Jun 14, 2005·The British Journal of Dermatology·K A PappUNKNOWN Etanercept Psoriasis Study Group
Nov 18, 2005·Clinical Therapeutics·Richard G B LangleyKenneth B Gordon
Apr 25, 2006·Journal of Cutaneous Medicine and Surgery·Kim A PappCatherine Zip
May 13, 2006·Archives of Dermatological Research·Kim A Papp

❮ Previous
Next ❯

Citations

Apr 25, 2006·Journal of Cutaneous Medicine and Surgery·Neil H ShearVincent Ho
Apr 25, 2006·Journal of Cutaneous Medicine and Surgery·Kim A PappCatherine Zip
Jun 30, 2009·Actas dermo-sifiliográficas·L PuigUNKNOWN Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología
Apr 16, 2009·Clinical Microbiology Reviews·Edsel Maurice T Salvana, Robert A Salata
Feb 21, 2014·The Journal of Dermatological Treatment·Susana ArmestoJorge Santos-Juanes
Nov 19, 2009·Journal of Cutaneous Medicine and Surgery·Norman WaselKim Papp

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.